Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis
Launched by GALDERMA R&D · Apr 9, 2008
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
Same as above.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of moderate to severe plaque psoriasis, defined as 3% - 20% treatable body surface area
- • Overall Disease Severity of at least 3 (moderate)
- Exclusion Criteria:
- • Surface area involvement too large (\>20% BSA)
- • Psoriasis involving only the scalp, groin, axillae, and/or other intertriginous areas
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Norfolk, Virginia, United States
San Diego, California, United States
Newnan, Georgia, United States
Norman, Oklahoma, United States
Snellville, Georgia, United States
Evansville, Indiana, United States
New York, New York, United States
Warren, Ohio, United States
College Station, Texas, United States
Houston, Texas, United States
Seattle, Washington, United States
Madison, Wisconsin, United States
Patients applied
Trial Officials
Ronald W Gottschalk, MD
Study Director
Galderma R&D
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials